Heron settles patent litigation with Mylan, grants generic license for CINVANTI/APONVIE starting June 2032

HERON THERAPEUTICS, INC. /DE/

Settlement resolves patent litigations in U.S. District Court for Delaware initiated in Sep 2023 and Jan 2024.
Heron grants Mylan a license to market generic CINVANTI and APONVIE beginning June 1, 2032 (or earlier under certain circumstances).
Patent protection for CINVANTI and APONVIE extends to 2035; license starts ~3 years before expiration.
Parties will file stipulation to dismiss pending litigations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.